氟脱氧胸苷PET-CT勾划食管癌大体肿瘤生物靶区长度的病理对照研究

目的 应用术后病理作为对照判断氟脱氧胸苷(FLT)PET-CT检测食管癌大体肿瘤生物靶区长度的最佳方法 和最佳界值,并与FDG PET-CT、CT、食管钡餐和食管镜进行直接对照研究.方法 24例患者行FLT PET-CT检查,其中22例行FDG PET-CT检查对照,全部患者均常规行食管钡餐、食管镜检查并均接受食管癌根治切除术.FLT PET-CT长度采用肉眼法,记为L_(FLTvisual),和采用SUV 1.3、1.4、1.5以及SUV_(max)的20%、25%和30%分别记为L_(FLT1.3)、L_(FLT1.4)、L_(FLT1.5)、L_(FLT20%)、L_(FLT25%)、L_(FLT30%);FDG PET-CT长度采用肉眼法、SUV 2.5和SUV_(max)的40%分别记为L_(FDGviaual)、L_(FDG2.5)、L_(FDG40%).CT、食管钡餐和食管镜所测得病变长度分别记为L_(CT)、L_(Scopy)和L_(X-ray)分别与术后病理长度L_(Path)进行比较.结果 L_(Path)值为(4.90±2.14)cm,各检测方法 所得病变长度由小到大依次为L_(FDG40%)、L_(Scopy)、L_(X-ray)、L_(FLT1.5)、L_(CT)、L_(FLT30%)、L_(FLTvis)、L_(FLT1.4)、L_(FLT25%)、L_(FDG2.5)、L_(FDGvis)、L_(FLT1.3)、L_(FLT20%),均数分别为(3.85±1.52)、(4.46±2.23)、(4.63±2.37)、(4.64±2.38)、(4.69±1.85)、(4.75±2.19)、(4.85±2.33)、(4.87±2.35)、(5.05±2.20)、(5.08±2.19)、(5.10 ±2.22)、(5.21 ±2.40)、(5.53±2.17)cm,与L_(Path)的相关系数分别为0.91、0.93、0.88、0.95、0.90、0.81、0.96、0.96、0.80、0.99、0.99、0.95、0.79,P值均为0.000.L_(FLT1.4)和L_(FDG2.5)分别为最佳FLT PET-CT和FDG PET-CT长度,且L_(FDG2.5)与L_(FLT1.4)相似(t=1.23,P=0.232).结论 最接近食管癌病理长度的FLT PET-CT界值为SUV 1.4,而FDG PET-CT的为SUV 2.5,可作为客观和简便易行的半定量分析指标.     

功能影像在食管癌精确放疗中的应用价值研究

目的 探讨PET-CT在食管癌临床分期诊断和三维适形放疗靶区勾画及治疗计划制定中的应用价值.方法 2007-2008年经病理证实的食管癌患者20例人组,其中2例接受手术治疗,18例行三维适形放疗.患者疗前行PET-CT模拟定位,比较食管镜、食管钡餐造影、CT、PET-CT_(SUV2.5)、PET-CT_(40%SUVmax)图像上的病变长度及最大横径,观察CT与PET-CT对临床分期诊断的差异.依据CT、PET-CT_(SUV2.5)和PET-CT<40%SUVmax>勾画靶区并制定治疗计划,评价3套计划受量情况.结果 食管镜、食管钡餐造影、CT、PET-CTS_(SUV2.5、PET-CT_(40%SUVmax))所示病变长度分别为4.93、5.06、6.67、5.89、4.84 cm,CT、PET-CT_(SUV2.5)、PET-CT_(40%SUV)所示病变最大横径分别为4.05、3.38、2.95 cm.CT图像诊断31个淋巴结转移,PET-CT图像诊断21个淋巴结转移,共同诊断14个,17个淋巴结CT诊断阳性而PET-CT为阴性,7个淋巴结CT诊断阴性而PET-CT为高代谢.5例患者经PET-CT模拟定位后M分期由Mn期改为_1期,1例经PET-CT模拟定位后由M_0期改为M_1期,1例CT和PET-CT M分期一致.依据CT和PET-CT_(SUV2.5)勾画的GTV基本相等2例,CTV_(CT)GT_(SUV2.5)者13例,GTV_(SUV2.5),相似文献   

4DCT、PET-CT与MRI勾画胸段食管癌大体肿瘤体积比较研究

目的 比较基于4DCT呼气末时相、¹⁸F-FDG PET-CT及T2加权(T2W) MRI所勾画胸段食管癌大体肿瘤体积(GTV)、位置及长度差异,探讨食管癌原发肿瘤GTV勾画时PET-CT与MRI图像结合的必要性。方法 26例拟行同步放化疗的胸段食管癌患者序贯完成增强3DCT、增强4DCT、PET-CT、增强MRI胸部定位扫描,基于3DCT图像形变配准。分别基于3DCT、4DCT的呼气末时相、PET-CT SUV 2.5、T2W-MRI和DWI图像勾画GTV获得GTVCT、GTV50%、GTVPET2.5、GTVMRI和GTVDWI。结果 GTVPET2.5大于GTV50%(P<0.001)和GTVMRI (P=0.008),而GTVMRI与GTV50%接近(P=0.439)。GTVMRI与GTV50%、GTVCT的适形指数(CI)大于GTVPET2.5与GTV50%、GTVCT的(P=0.004、P=0.039),GTVMRI与GTVPET2.5的CI明显小于GTVMRI、GTVPET2.5与GTV50%、GTVCT的(P=0.000~0.021)。镜检长度与GTVPET、GTVDWI长度相近(P>0.05),且GTVPET2.5与GTVDWI长度接近(P=0.072)。结论 基于PET-CT SUV2.5与呼吸门控状态下T2W-MRI所勾画食管癌GTV和空间位置差异明显,PET-CT与MRI结合进行食管癌靶区勾画的必要性尚需探讨,但MRI-DWI可以代替PET-CT帮助基于CT图像勾画GTV时上下界的确定。     

18FDG PET-CT双时相显像在非小细胞肺癌肺门纵隔淋巴结累及野放疗靶区勾画中的价值

目的 探讨18FDG PET-CT双时相显像在非小细胞肺癌(NSCLC)肺门纵隔淋巴结累及野放疗靶区勾画中的价值.方法 选取行手术治疗的NSCLC患者54例,术前3～5 d内行18FDG PET.CT常规全身显像和胸部延迟显像,以术后病理诊断结果为标准,比较根据常规显像和双时相显像结果勾画的淋巴结累及野放疗靶区的不同.结果 肺门淋巴结靶区39%患者GTV常规与GTV病理一致,57%患者GTV双时相与GTV病理一致;AGTV1(GTV常规-GTV病理)=32.64 cm3,AGTV2(GTV双时相-GTV病理)=22.57 cm3,后者比前者变化少(u=519.00,P=0.023).纵隔淋巴结靶区56%患者GTV常规与GTV病理一致,67%患者GTV双时相与GTV病理一致;ΔGTV1=22.85 cm3,ΔGTV2=20.95 cm3,后者与前者变化相似(u=397.50,P=0.616).结论 根据18FDG PET-CT双时相显像结果勾画的NSCLC肺门纵隔转移性淋巴结靶区更接近于根据病理结果勾画的靶区,双时相显像较常规显像能更好地指导淋巴结累及野靶区的勾画.     

FDG PET-CT与MRI在鼻咽癌原发灶靶区勾画中的对比研究

目的 对比研究FDG PET-CT不同勾画方法间及与MRI显示鼻咽原发灶靶区差异,探讨FDG PET-CT勾画鼻咽原发灶大体肿瘤体积(GTV)生物靶区的可行性。方法 50例初治鼻咽癌患者治疗前均行FDG PET-CT和MRI检查,先在MRI图像上勾画GTV得到GTV-MRI,然后在FDG PET-CT上分别用目测法或不同阈值法(30%、40%、50%SUV_max)勾画GTV得到GTV-PET_vis、GTV-PET₃₀、GTV-PET₄₀、GTV-PET₅₀。采用Wilcoxon检验GTV-PET不同方法间和GTV-MRI差异,以及不同T分期中不同勾画方法间差异。结果 全组GTV-MRI、GTV-PET_vis、GTV-PET₃₀、GTV-PET₄₀、GTV-PET₅₀分别为27.8、22.2、22.7、14.4、9.0 cm³,除GTV-PET_vis与GTV-PET₃₀间(Z=－0.05,P=0.958)以及T_1~2期(25例) GTV-MRI与GTV-PET_vis和GTV-PET₃₀相似外(Z=－0.93、－0.93,P=0.353、0.353),其余均不同(Z=－5.74~－2.09,P=0.000~0.037)。结论 应用FDG PET-CT不同方法勾画的GTV-PET均max为阈值自动勾画鼻咽原发灶GTV可实现生物代谢肿瘤体积范围勾画。     

基于DWI及18F-FDG PET-CT勾画胸段食管癌大体肿瘤体积变化与比较

目的 探讨基于食管癌原发肿瘤弥散加权像(DWI)高信号区域指导个体化局部加量放疗的可行性。方法 对比32例胸段食管癌患者放疗前和放疗第15次时增强3DCT、¹⁸F-FDG PET-CT及增强MRI定位扫描图像,基于放疗前和放疗中3DCT、PET-CT及基于MRI的DWI与T2WI融合图像勾画食管癌大体肿瘤体积(GTV)并分别定义为GTVCTpre和GTVCTdur、GTVPETpre和GTVPETdur、GTVDWIpre和GTVDWIdur,分别测量放疗前及放疗中标准摄取值(SUV)、代谢肿瘤体积(MTV)、病灶糖酵解总量(TLG)、表观弥散系数(ADC)并计算其变化。结果 治疗前与治疗中基于PET-CT和DWI图像所勾画食管癌GTV体积及其变化与相应增强3DCT之间均呈正相关(均P<0.001);SUV、MTV、TLG、ADC差异均有统计学意义(均P<0.001);无论治疗前还是治疗中GTV的SUV与ADC、△SUV与△ADC均无相关性(均P>0.05);GTVPETpre与GTVDWIpre间适形指数(CI)明显高于GTVPETdur与GTVDWIdur间的CI (P<0.001);基于DWI的GTV最大径退缩率及体积退缩率均>基于PET者(24%∶14%,P=0.017;60%∶41%,P<0.001)。结论 无论放疗前还是放疗中食管癌SUV与ADC值、△SUV与△ADC均无相关性;放疗中期基于PET-CT图像高FDG摄取区勾画的GTV与基于DWI高信号区勾画者空间位置差异明显,且后者GTV退缩率明显大于前者。因此,放疗中基于DWI高信号区的变化进行放疗后程食管癌局部加量照射的可行性并不明确。     

不同影像检查在鼻咽癌靶区勾画中的应用

目的应用CT、MRI和18FDG-PET-CT对鼻咽癌原发病灶GTV大小进行比较,为临床治疗计划的设计提供最优的影像学检查和靶区勾画建议.方法连续选取放疗科从2006年9月至2006年11月,病理确诊的鼻咽癌患者34例进行研究.所有患者在未作任何抗肿瘤治疗之前,采用统一的体位及固定方法,行头颈部的CT和MRI平扫及增强扫描、全身18FDG-PET-CT三种检查.全部患者分别在增强CT、MRI T2加权和PET-CT上勾画原发灶GTV.结果GTVCT(27.31±15.53cm3)＞GTVMRI(26.30±17.93 cm3)＞GTV2.5(18.43±12.93 cm3)＞GTV45(13.20±11.22 cm3),GTVCT/GTVMRI与GTV2.5/GTV45间有统计学意义;对于早期病例(T1、T2),GTVCT＞GTVMRI,差异有统计学意义(P=0.012),而对于晚期病例(T3、T4),GTVCT＜GTVMRI,差异无统计学意义.结论在鼻咽癌原发病灶靶区勾画方面,以SUV＝2.5或最大SUV的45%阈值法为标准,PET在GTV的确定上小于CT和MRI,差异经统计学处理有意义;CT和MRI在GTV的确定上差异无统计学意义,但是对于T1、T2局部早期病例的GTV,CT大于MRI,差异具有统计学意义.从影像学特点上考虑,对于GTV的准确确定,MRI比CT更有价值;PET-CT作为辅助显像方法提供CT所不能发现的病灶信息,作为靶区勾画的参考.     

食管鳞癌18F-FDGPET图像异质性及其对放疗靶区勾画影响分析

目的:探讨18氟-氟代脱氧葡萄糖(18 F-fluorodeoxyglucose,18 F-FDG)PET图像异质性对食管癌放疗靶区勾画的影响。方法:28例经病理确诊为食管鳞癌初治患者治疗前行18 F-FDG PET/CT扫描。通过视觉法和三维图像纹理参数(能量和熵)分析获得FDG摄取异质性。CT图像上勾画出肿瘤靶区(GTVCT)。PET图像上肿瘤靶区采用自动勾画法,分别采用40%SUVmax阈值勾画(GTVPET40%)和标准化摄取值(standardized uptake value,SUV)=2.5绝对值阈值勾画(GTVPET2.5)。分析FDG摄取异质性与不同方法勾画肿瘤靶区体积差值间的相关性。结果:3种方法获得的肿瘤靶区差异有统计学意义,GTVCT为(45.00±43.40)cm3明显大于GTVPET40%的(20.42±16.12)cm3和GTVPET2.5(35.88±36.33)cm3,其中GTVCT与GTVPET40%差异有统计学意义,t=4.34,P=0.00;GTVCT与GTVPET2.5差异有统计学意义,t=4.80,P=0.00;GTVPET40%与GTVPET2.5:差异有统计学意义,t=3.59,P=0.00。肿瘤摄取异质性与传统代谢参数SUVmax和SUVmean及靶区体积间存在相关性,|r|=0.41,P≤0.03。GTVPET40%和GTVPET2.5之间的差异与熵呈正相关,r=0.41,P=0.029;与能量负相关,r=-0.39,P=0.04。视觉评分与GTVPET40%和GTVPET2.5之间的百分率差值也存在相关性,r=0.59,P=0.001。结论:PET图像上靶区勾画受到FDG摄取异质性的影响,特别是异质性较大的肿瘤。PET精确靶区勾画方法需要考虑到肿瘤异质性的影响。     

PET-CT用于评价食管鳞癌放疗中18F-FDG高摄取区域的空间动态变化的前瞻性研究

背景与目的：放疗为食管癌重要的治疗方式之一,但疗效并不理想。目前认为肿瘤在PET-CT上高摄取的区域可能与放射抵抗有关。本文通过观察放疗前和放疗中两次PET-CT所显示的食管原发病灶18F-FDG高摄取区域的空间位置关系,从而推测依据放疗前的PET图像上所显示的食管癌原发灶高18F-FDG摄取的信息进行区域选择性加量放疗的可行性。方法：入组2011—2013年在复旦大学附属肿瘤医院放疗科接受同步放化疗治疗的初治食管鳞癌患者。所有患者在放疗前和放疗40 Gy时(第2次同步化疗前)分别行18F-FDG PET-CT扫描。在第1次PET图像上原发灶勾画首先以标准摄取值(standard uptake value,SUV)=2.5、5和40%~70%SUVmax-pre为阈值在PET图像上自动勾画得到大体肿瘤体积(gross tumor volume,GTV)2.5pre、GTV5pre、GTV40%pre、GTV50%pre、GTV60%pre和GTV70%pre。在第2次PET图像上,以SUV=2.5和70%~90%SUVmax-dur为阈值勾画得到GTV2.5dur、GTV70%dur、GTV80%dur和GTV90%dur。计算两次PET图像上以阈值自动勾画的区域的空间交集分数(overlap fraction,OF),即两个感兴趣区(region of interest,ROI)的交集的体积与两个ROI相对较小的体积的比值。结果：共入组22例患者。所有患者的原发灶SUVmax、SUVmean均有显著下降(P=0.003和P<0.0001)。残留高摄取区域与治疗前GTV50%pre的OF达到70%以上,其中热点区域GTV90%dur完全处于原发灶的高摄取区域内,OF达到100%。以不同阈值勾画的体积有很大差异,而放疗前和放疗中的食管癌原发灶高代谢区域尽管体积变化很大,但空间位置保持相对的稳定。结论：放疗中食管鳞癌原发灶的SUV显著下降,但食管癌原发灶残留的18F-FDG高摄取区域仍然较稳定的落在治疗前原发灶GTV及治疗前PET上所显示的18F-FDG高摄取区域内,提示依据治疗前PET图像来选择性对食管癌原发病灶的部分区域进行局部加量放疗是可行的。     

氟脱氧葡萄糖PET-CT确定食管癌淋巴结放疗靶区的可行性研究

目的分析~(18)FDG PET-CT诊断食管癌淋巴结转移的优势及确定淋巴结放疗靶区的可行性。方法回顾性分析30例食管癌患者的临床病理资料,分析PET-CT在诊断淋巴结转移方面的优势,基于CT和PET-CT确定淋巴结大体肿瘤靶区(GTVN)和临床靶区(CTVN),根据术后病理分析PET-CT在确定淋巴结放疗靶区中的价值。结果13例由CT确定的GTVN(GTVN-CT)与病理一致,19例基于PET-CT的GTVN(GTVN-PET-CT)与病理相符。对照淋巴结病理结果,PET-CT改变了15例由CT确定的GTVN和其中10例的CTVN。PET-CT导致GTV缩小(GTVN-PET-CTGTVN- CT的12例共涉及22组淋巴结,其中9例CTVN亦扩大。GTVN-PET-CT>GTVN-CT的亚组分析显示,PET-CT确定的淋巴结GTV准确率高于CT(67%:25%,P=0.041)。结论PET-CT在诊断淋巴结转移中的优势使之可作为优化和确定食管癌淋巴结放疗靶区的有用工具。     

外泌体在肿瘤发展中的研究进展

外泌体是细胞经过"内吞-融合-外排"等一系列调控过程而形成的细胞外纳米级小囊泡。外泌体可以携带蛋白,运送RNA,在细胞间物质和信息转导中起重要作用。外泌体可能通过调控免疫功能,促进肿瘤血管新生和肿瘤转移,以及直接作用于肿瘤细胞等途径,影响肿瘤的进展。外泌体可应用于肿瘤的诊断。本文总结了近年来有关外泌体在肿瘤发展中作用的研究进展。     

Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo

The aim of the present study was to test the ability of the chemotherapeutic agent suramin to inhibit angiogenesis in experimental models in vitro and in vivo. In the culture of rat aortic rings on fibronectin, suramin dose-dependently inhibited vascular cell growth, achieving the maximal effect (mean − 88% versus controls, P < 0.05) at 400 μg/ml. Image analysis showed that suramin could inhibit microvessel sprouting in fibrin from rat aortic rings as evaluated by the ratio between the cellular area and the mean gray value of the sample (sprouting index); suramin at 50 μg/ml significantly reduced the sprouting index from the control value of 0.35 ± 0.04 to 0.14 ± 0.02 mm²/gray level (P < 0.05). Likewise, the area occupied by cells was 19.2 ± 1.8 mm² as compared with 41.8 ± 4.2 mm² in controls (P < 0.05). In the rat model of neovascularization induced in the cornea by chemical injury, suramin at 1.6 mg/eye per day reduced the length of blood vessels (0.7 ± 0.1 mm as compared with 1.5 ± 0.1 mm in controls, P < 0.05). In the same model the ratio between the area of blood vessels and the total area of the cornea (area fraction score) was decreased by suramin from 0.19 ± 0.02 in controls to 0.03 ± 0.003 (P < 0.05). Suramin given i.p. at 30 mg/kg per day markedly inhibited the neovascularization induced in the rat mesentery by compound 48/80 or conditioned medium from cells secreting the angiogenic protein fibroblast growth factor-3 (FGF-3). The area fraction score in control rats treated with compound 48/80 was 0.31 ± 0.03, and this was reduced to 0.07 ± 0.01 by suramin (P < 0.05). After i.p. administration of FGF-3 the area fraction score was reduced by suramin from 0.29 ± 0.03 to 0.05 ± 0.01 (P < 0.05). These results provide evidence that suramin exerts inhibitory effects on angiogenesis in both in vitro and in vivo models. Received: 9 January 1998 / Accepted: 29 June 1998     

Evaluation of the antitumoral effect of dihydrocucurbitacin-B in both in vitro and in vivo models

Aims  We evaluated both in vitro and in vivo antitumoral properties of an isolated compound from Wilbrandia ebracteata, dihydrocucurbitacin-B (DHCB), using B16F10 cells (murine melanoma). Materials and methods  We made use of MTT and ³H-Thymidine assays to investigate the cell viability and cell proliferation, flow cytometry analysis to monitor cell cycle and apoptosis, western blot analysis to evaluate the expression of cell cycle proteins, imunofluorescence analysis and in vivo tumor growth and metastasis. Results  Dihydrocucurbitacin-B significantly reduced cell proliferation without important effects on cells viability. DHCB lead cells to accumulate in G2/M phases accompanied by the appearance of polyploid cells, confirmed by fluorescence assays that demonstrated a remarkable alteration in the cell cytoskeleton and formation of binuclear cells. Annexin-V-FITC incorporation demonstrated that DHCB did not induce apoptosis. About 10 μg/mL DHCB was found to decrease cyclin-A, and especially in cyclin-B1. The in vivo experiments showed that DHCB treatment (once a day up to 12 days; p.o.) was able to reduce the tumor growth and lung metastasis up to 83.5 and 50.3%, respectively. Conclusions  Dihydrocucurbitacin-B reduces cell proliferation due to a decrease in the expression of cyclins, mainly cyclin-B1 and disruption of the actin cytoskeleton, arresting B16F10 cells in G2/M phase. Taken together, the in vitro and in vivo experiments suggest that DHCB was effective against cancer, however, it remains to be proved if DHCB will be a good candidate for drug development.     

胶质瘤中微RNA研究进展

微RNA(microRNA,miR)可在转录后水平负调控靶基因表达,miR异常表达与肿瘤生成密切相关.对胶质瘤中多个miR异常表达及其机制的研究将对进一步探讨胶质瘤的分子病理及其诊治开拓新途径.     

重组人血管内皮抑制素治疗恶性肿瘤的研究进展

重组人血管内皮抑制素(恩度)是一种广谱的抗血管生成分子靶向药物,主要循证证据为联合化疗治疗晚期非小细胞肺癌(NSCLC).近年来,重组人血管内皮抑制素用于治疗多种恶性肿瘤的研究逐渐增多,并取得了较好的疗效.此外,有关重组人血管内皮抑制素联合治疗手段、给药途径、给药方法的研究逐渐开展,有利于其合理应用.     

Effect of trauma of implantation of metastatic tumor in bone in mice

We studied the influence of surgical trauma to the iliac bone on the implantation of I. V. injected tumor cells, which formed tumor in the surgical wounds of 27/84 mice (32%). None of these mice or nonsurgical mice developed tumor in the opposite or uninjured pelvic bone (P < 0.0001). When different numbers (10⁵, 5 × 10⁵, and 10 × 10⁵) of TA3Ha cells were injected I. V. immediately after surgery, the frequency of tumor formation showed an increase (respectively, 32%, 63%, 71%). As the interval between induction of trauma and tumor cell injection was increased from 0 to 15 days, the frequency of tumor formation declined from 32% to 0%. These results suggest that the healing wound is a privileged site for experimental metastasis, particularly in the early stages. It is likely that the proteins in the blood clotting cascade are involved in local tumor implantation. © 1994 Wiley-Liss, Inc.     

Survey of changes in dietary preferences in cancer patients in China

Objective The aim of this study was to investigate the changes in dietary preferences in cancer patients in China and to determine the need for encouraging the adherence to a sensible diet among such patients.Methods A total of 468 cancer patients were interviewed using a self-designed questionnaire focusing on changes in the intake of specific foods. Data were analyzed using SPSS 16.0. Results Most patients completely avoided roosters and carp(73.1%), condiments(51.9%), and meat of aquatic species(40.4%). All other types of the specific foods were completely avoided by different subpopulations of the patients.Conclusion In addition to focusing on disease treatment, medical professionals need to help cancer patients overcome barriers associated with the customs of avoiding specific foods encompassed by the term ”fawu” and provide them with dietary guidance in order to prevent negative nutritional effects.     

中国乳腺癌患者生活质量研究进展

生活质量（qualityoflife,QOL）又译作生命质量、生存质量,它是在世界卫生组织提倡的健康新概念“人们在躯体上、精神上及社会生活中处于一种完好的状态,而不仅仅是没有患病和衰弱”的基础上构建的,是医学模式由生物医学模式向生物一心理一社会医学模式转变的体现。西方发达国家已将此概念广泛应用于临床试验、卫生政策制定和卫生资源效益评价等众多领域。生存质量已作为评价肿瘤患者术后状况的首选指标。     

Contribution of FDG-PET in the management of pediatric sarcomas in 2011

FDG-PET has boomed in recent years for diagnosis, staging and the search for recurrence of a large number of tumors. This is particularly true for soft tissue sarcomas and musculoskeletal sarcomas, for which the first publications on the potential role of FDG-PET dating back to the early 1990s. The majority of published studies on adult sarcomas confer, possibly a mixed population. Studies dedicated to pediatrics population are much rarer. The "Standards, Options and Recommendations" of the French Federation of Anticancer Centers published in 2003 on "The use of FDG-PET in oncology" and make recommendations and expert advices as part sarcomas of adult patients. After a first part dedicated to the particular interpretation of FDG PET in children, the purpose of this paper is to review the potential contribution of this exam in the treatment of pediatric sarcomas.